FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114725672> ?p ?o ?g. }

• W2114725672 endingPage "2022" @default.
• W2114725672 startingPage "2022" @default.
• W2114725672 abstract "We thank Kang et al. [1.Kang Y.K. Kang W.K. Shin D.B. et al.Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.Ann Oncol. 2009; 20: 666-673Abstract Full Text Full Text PDF PubMed Scopus (645) Google Scholar] for their trial ML17032 published in the recent issue of Annals of Oncology. This confirmed the noninferiority of capecitabine to infusional 5-fluorouracil as part of palliative combination chemotherapy for advanced gastric cancer. In the accompanying editorial, Wong and Cunningham [2.Wong R. Cunningham D. Optimising treatment regimens for the management of advanced gastric cancer.Ann Oncol. 2009; 20: 605-608Abstract Full Text Full Text PDF PubMed Scopus (20) Google Scholar] make the important point that current evidence indicates doublet chemotherapy regimens are inferior to triplet regimens in this setting. We would like to raise awareness to the mismatch that exists between the physician selected trial populations upon which this evidence relies and the real-world populations that comprise advanced gastric and oesophageal cancer. The degree of selection is illustrated by the median age in the ML17032 study which was 56 years (range 22–74 years). This compares with the typical gastric cancer population where, for example, in the UK, the median age at death is 77 years with 82% of patients being over the age of 70. This problem underlies the entire evidence base for palliative chemotherapy in this tumour type. The REAL-2 trial, the largest trial to date has a median patient age of 63 [3.Cunningham D. Starling N. Rao S. et al.Capecitabine and oxaliplatin for advanced esophagogastric cancer.N Engl J Med. 2008; 358: 36-46Crossref PubMed Scopus (1785) Google Scholar]. In spite of attempts to address this problem with pooled analyses [4.Trumper M. Ross P.J. Cunningham D. et al.Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: a pooled analysis of three clinical trials.Eur J Cancer. 2006; 42: 827-834Abstract Full Text Full Text PDF PubMed Scopus (84) Google Scholar], level 1 evidence is lacking for a large cohort of these patients. This issue is not unique to upper gastrointestinal cancer and the ageing population in the Western world can be expected to lead to a marked increase in the number of elderly patients seeking treatment over the coming decades. One might argue that the focus of evidence on the younger minority accurately reflects sensible use of chemotherapy by limiting it to those in whom the risk–benefit trade-off is likely to be favourable. However, evidence indicates that age is not a negative predictive factor for response or a negative prognostic factor for survival outcomes in gastric or oesophageal cancer [5.Chau I. Norman A.R. Cunningham D. et al.Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer—pooled analysis from three multicenter, randomized, controlled trials using individual patient data.J Clin Oncol. 2004; 22: 2395-2403Crossref PubMed Scopus (398) Google Scholar]. It may be that the toxicity of triplet or even doublet regimens may indeed outweigh any anticancer benefit in the elderly. Only by assessing single-agent, doublet and triplet therapy at appropriate doses in the elderly population, we will secure a comprehensive evidence base and determine a standard treatment in this important group of patients." @default.
• W2114725672 created "2016-06-24" @default.
• W2114725672 creator A5043150762 @default.
• W2114725672 creator A5058562981 @default.
• W2114725672 creator A5085866945 @default.
• W2114725672 date "2009-12-01" @default.
• W2114725672 modified "2023-09-25" @default.
• W2114725672 title "Are we representing the true population in oncology trials?" @default.
• W2114725672 cites W1967103434 @default.
• W2114725672 cites W2127773543 @default.
• W2114725672 cites W2128328462 @default.
• W2114725672 cites W2163258399 @default.
• W2114725672 cites W2167112387 @default.
• W2114725672 doi "https://doi.org/10.1093/annonc/mdp461" @default.
• W2114725672 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32560026" @default.
• W2114725672 hasPublicationYear "2009" @default.
• W2114725672 type Work @default.
• W2114725672 sameAs 2114725672 @default.
• W2114725672 citedByCount "4" @default.
• W2114725672 countsByYear W21147256722013 @default.
• W2114725672 countsByYear W21147256722015 @default.
• W2114725672 countsByYear W21147256722023 @default.
• W2114725672 crossrefType "journal-article" @default.
• W2114725672 hasAuthorship W2114725672A5043150762 @default.
• W2114725672 hasAuthorship W2114725672A5058562981 @default.
• W2114725672 hasAuthorship W2114725672A5085866945 @default.
• W2114725672 hasConcept C121608353 @default.
• W2114725672 hasConcept C126322002 @default.
• W2114725672 hasConcept C143998085 @default.
• W2114725672 hasConcept C2776694085 @default.
• W2114725672 hasConcept C2777909004 @default.
• W2114725672 hasConcept C2778336483 @default.
• W2114725672 hasConcept C2908647359 @default.
• W2114725672 hasConcept C526805850 @default.
• W2114725672 hasConcept C71924100 @default.
• W2114725672 hasConcept C99454951 @default.
• W2114725672 hasConceptScore W2114725672C121608353 @default.
• W2114725672 hasConceptScore W2114725672C126322002 @default.
• W2114725672 hasConceptScore W2114725672C143998085 @default.
• W2114725672 hasConceptScore W2114725672C2776694085 @default.
• W2114725672 hasConceptScore W2114725672C2777909004 @default.
• W2114725672 hasConceptScore W2114725672C2778336483 @default.
• W2114725672 hasConceptScore W2114725672C2908647359 @default.
• W2114725672 hasConceptScore W2114725672C526805850 @default.
• W2114725672 hasConceptScore W2114725672C71924100 @default.
• W2114725672 hasConceptScore W2114725672C99454951 @default.
• W2114725672 hasIssue "12" @default.
• W2114725672 hasLocation W21147256721 @default.
• W2114725672 hasLocation W21147256722 @default.
• W2114725672 hasOpenAccess W2114725672 @default.
• W2114725672 hasPrimaryLocation W21147256721 @default.
• W2114725672 hasRelatedWork W1819925999 @default.
• W2114725672 hasRelatedWork W2037370137 @default.
• W2114725672 hasRelatedWork W2139955290 @default.
• W2114725672 hasRelatedWork W2160763249 @default.
• W2114725672 hasRelatedWork W2275049615 @default.
• W2114725672 hasRelatedWork W2417717847 @default.
• W2114725672 hasRelatedWork W2747668683 @default.
• W2114725672 hasRelatedWork W3041235120 @default.
• W2114725672 hasRelatedWork W3082163037 @default.
• W2114725672 hasRelatedWork W3164870680 @default.
• W2114725672 hasVolume "20" @default.
• W2114725672 isParatext "false" @default.
• W2114725672 isRetracted "false" @default.
• W2114725672 magId "2114725672" @default.
• W2114725672 workType "article" @default.